ADDvise receives allocation decision worth approximately MSEK 2.2 – Regulatory information

ADDvise Group AB (publ) subsidiary Sonar Oy has received an allocation decision from Kangasala town in Finland worth approximately MSEK 2.2. The allocation decision consists of an order, and with the possibility for a second order with the same value, regarding a digital radiography (DR) system used for image capturing.

The decision is subject to an appeal time expiring 11 March 2020.

ADDvise Group AB (publ) has adopted new guidelines regarding the assessment of information affecting the financial instrument and the disclosure thereof. Entailing that orders and investments within the group with an aggregate value of at least MSEK 5 are to be considered as information affecting the financial instrument and shall be published to the market through a press release. However, the assessment of whether the information may affect the financial instrument is based on the facts and circumstances in the specific case.
 

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 26, 2020 at 17:25 CET.
 

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.